A Single and Multiple Dose-escalation First-in-human With Food-effect Study Evaluating the Safety, Tolerability and Pharmacokinetics of SRT-015 Administered Orally
Latest Information Update: 26 Dec 2022
At a glance
- Drugs SRT-015 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Seal Rock Therapeutics
- 08 Nov 2022 Results (n=69) assessing the safety and tolerability of single and repeat ascending doses of SRT-015 in healthy volunteers, presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases.
- 24 Oct 2022 According to a Seal Rock Therapeutics media release, data will be presented at The Liver Meeting of the American Association for the Study of Liver Diseases (AASLD).
- 19 Apr 2022 Status changed from recruiting to completed.